Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing cancer therapeutics that either extend lives or improve patient quality of life. They aim to use their scientific and clinical expertise to reduce risk and accelerate clinical development of drug candidates. Monopar was founded in 2014 with current facilities located in San Francisco, CA and Chicago, IL.

Monopar Therapeutics

424B5

Monopar Receives Clearance to Proceed with Phase 1 - GlobeNewswire

 Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule 

 Monopar Announces First Patient Enrolled in First-in-Human 

 Monopar Announces CFO Succession 

 Camsirubicin Leads to Tumor Size Reduction in 2 Patients ... 

symbol__ Stock Quote Price and Forecast - CNN

 Monopar Announces Encouraging Clinical Data from Ongoing Camsirubicin Phase 1b Trial 

 Monopar stock jumps 60% amid preclinical data for MNPR-101 


                Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments            

EX-10

How the (MNPR) price action is used to our Advantage - Stock Traders Daily

What Makes Monopar Therapeutics (MNPR) a Good Fit for 'Trend Investing' - Yahoo Finance

EX-99.1

Monopar retrieves Wilson disease candidate from AstraZeneca's scrap heap - Fierce Biotech


                Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference            

Monopar’s MNPR-101-Lu receives Australian HREC clearance for trial in advanced cancers - BioWorld Online

Monopar Therapeutics announces pricing of $40M public offering of common stock - MSN

Individual investors are Monopar Therapeutics Inc.'s (NASDAQ:MNPR) biggest owners and were rewarded after market cap rose by US$40m last week - Yahoo Finance

 Monopar, NorthStar enhance radiopharma collaboration By Investing.com 

What's Going On With Monopar Therapeutics Shares Friday? - Benzinga

Monopar Therapeutics Reports Second Quarter 2024 Financial Results and Recent Developments - GlobeNewswire

 Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu 

We Think Monopar Therapeutics (NASDAQ:MNPR) Needs To Drive Business Growth Carefully - Simply Wall St

EX-10.5

EX-5.1

We're #hiring a new Senior Clinical Project Manager in Wilmette, Illinois. Apply today or share this post with your network.

Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers - GlobeNewswire

Monopar stock climbs as it takes over Wilson disease drug candidate (NASDAQ:MNPR) - Seeking Alpha

Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments - The Manila Times

Monopar Therapeutics sets stock and warrant offering prices By Investing.com - Investing.com South Africa

EX-10.6

Annual Meeting

EX-31.1

Contacts

Monopar Therapeutics Inc.

EX-10.9

Monopar Therapeutics Closes $19.2 Million Stock Offering - TipRanks

Monopar Therapeutics Skyrockets 400% on Licensing Deal - MarketBeat

Monopar stock soars to 52-week high, hits $8.75 - Investing.com


               HTML
            

Best-Performing Small-Cap Stocks of 2024 - Investing.com

Governance Documents

Monopar Therapeutics sets stock and warrant offering prices - Investing.com

 Monopar initiates radiopharma phase 1 trial for its advanced cancer treatment 

 Monopar reports preclinical data on MNPR-101 radiopharmaceutical program 

 Monopar and Northstar expand collaboration with new radiolabeled MNPR-101 imaging candidate 

 Monopar Therapeutics (MNPR) Stock: Why It Increased Over 2.5% Today 


              Presentations
            

10-K

Here's Why We're Watching Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Situation - Yahoo Finance

EX-10.4

EX-10.10

Rallybio reins in preclinical R&D, while Monopar pivots to radiopharma to eke out cash - Fierce Biotech

 Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients 

SC 13D/A

Monopar Therapeutics Announces Strategic Reverse Stock Split - TipRanks

 Monopar to Present at the 35th Annual Roth Conference 

10-Q Filing

Monopar shares hold as analyst reiterates $9 target on trial data - Investing.com

Initial statement of beneficial ownership of securities


              Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate
            

Monopar Therapeutics puts the brakes on IPO, again

EX-3.2

 Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers 

Quarterly Reports

Monopar Therapeutics (NASDAQ:MNPR) Hits New 52-Week High - Still a Buy? - MarketBeat

EX-32.1

 HTML

EX-10.16

Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate - StockTitan

Analyst Coverage

Monopar Therapeutics Expands Portfolio with New Patent Filing - Yahoo Finance


              Monopar and NorthStar Amend & Extend Collaboration
            

 Monopar stock jumps 60% amid preclinical data for MNPR-101 (NASDAQ:MNPR) 

RA Capital Management, L.P. Acquires New Stake in Monopar Therap - GuruFocus.com

 Monopar Announces Encouraging Camsirubicin Phase 1b Trial Update 

View All News

Monopar Therapeutics (MNPR) Shares Surge on Partnership with Ale - GuruFocus.com

Monopar Therapeutics CFO buys $25,187 in common stock - Investing.com

Why Is Monopar Therapeutics Stock Surging Over 400% On Thursday? - AstraZeneca (NASDAQ:AZN), Monopar Therapeutics (NASDAQ:MNPR) - Benzinga

EX-10.15

EX-10.14

Up 600% Then Down 50% In 2 Days: What Is Going On With MNPR Stock? - Forbes

MNPR Stock Skyrockets 384% in 3 Months After Deal With AZN - Yahoo Finance

Monopar Therapeutics Inc (MNPR-Q) Quote - Press Release - The Globe and Mail

 Jones Trading upgrades Monopar to buy, PT lifted 

 Monopar files patent protecting its MNPR-101 radiopharma optimization findings 

 Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101 ... 

 Monopar and NorthStar Amend & Extend Collaboration 

EX-21

Monopar Up 450% - Were You On Board? - RTTNews

Here's What Could Help Monopar Therapeutics (MNPR) Maintain Its Recent Price Strength - MSN

Monopar Therapeutics Reports Positive MNPR-101-Zr Trial Results - TipRanks

 Monopar's radiopharmaceutical cleared to enter phase I in Australia for advanced cancers 


                Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu            

Monopar Therapeutics

Business:

Drug notes:

About: